Exploring Notch-specific targets such as NOTCH3-targeted antibody drug conjugates and/or NOTCH4 monoclonal antibodies can help determine if there is greater tumor response and less toxicity with more specific targeted therapy in uLMS [46,47,48]. Here, NOTCH4 is linked to neoplasm.